Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience.
Jeremy ErDavid RoutledgeJennifer HemptonColin WoodTrish JoyceSimon James HarrisonPhilip CampbellPublished in: Internal medicine journal (2021)
There are currently limited Australian data on the outcomes of autologous stem cell transplantation (ASCT) in elderly multiple myeloma (MM) patients. We present the largest cohort of elderly MM patients aged ≥65 years undergoing ASCT in Australia and report their outcomes based on our two-centre experience. Our study affirms that ASCT is well tolerated, safe and effective in elderly MM patients aged ≥65 years and should be considered an important component of treatment in patients who are fit enough for the procedure.
Keyphrases
- stem cell transplantation
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- multiple myeloma
- high dose
- adipose tissue
- patient reported outcomes
- mesenchymal stem cells
- insulin resistance
- electronic health record
- cell therapy
- weight loss
- big data
- community dwelling
- patient reported
- glycemic control